S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL

• Ruben Van Dijck,
• Ron VAN DER Holt,
• Ellen Meijer,
• Timothy Devos,
• Mette Hazenberg,
• Marjolein Van Der Poel,
• Dimitri Breems,
• Lien Deleu,
• Nicolaas Schaap,
• Peter André Willem Te Boekhorst

Affiliations

Ruben Van Dijck

1 Erasmus University Medical Center, Hematology, Rotterdam, The Netherlands

Ron VAN DER Holt

1 Erasmus University Medical Center, Hematology, Rotterdam, The Netherlands

Ellen Meijer

2 Amsterdam University Medical Center, Hematology, Amsterdam, The Netherlands

Timothy Devos

3 Leuven University Hospitals, Hematology, Leuven, Belgium

Mette Hazenberg

2 Amsterdam University Medical Center, Hematology, Amsterdam, The Netherlands

Marjolein Van Der Poel

4 Maastricht University Medical Center, Hematology, Maastricht, The Netherlands

Dimitri Breems

5 Ziekenhuisnetwerk Antwerpen, Hematology, Antwerpen, Belgium

Lien Deleu

6 AZ Delta, Hematology, Roeselare, Belgium

Nicolaas Schaap

7 Radboud University Medical Center, Hematology, Nijmegen, The Netherlands

Peter André Willem Te Boekhorst

1 Erasmus University Medical Center, Hematology, Rotterdam, The Netherlands